Yumin Zhuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yumin Zhuo has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Zheng Chen
Department of Urology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, People’s Republic of China
8 shared publications- Zheng Chen
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China
7 shared publications Xiaoping Qin
Department of Urology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
5 shared publicationsJue Wang
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China
4 shared publicationsLiwei Wei
Department of Urology, The First Affiliated Hospital of Jinan University, Jinan University
3 shared publicationsXiao-Ping Qin
Department of Urology, The First Affiliated Hospital of Jinan University
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (46) , e51493
Circulating inflammatory proteins mediate the causal relationship between blood alliin and cancer: A two-step, multivariable Mendelian randomization study
An association has been found between alliin and reduced risks of various cancers; however, evidence for these causal relationships remain limited. This study utilized Mendelian randomization (MR) analysis to assess the potential causal relationships between circulating alliin levels and the risks of 22 common cancers. We selected instrumental variables from the latest and largest European genome-wide association study (GWAS) datasets. First, we comprehensively assessed the causal relationships between blood alliin levels and the risks of 22 common cancers through two-sample MR analysis. Subsequently, we repeated the validation of instrumental variables using cancer GWAS statistics from different studies and merged the results by meta-analysis. Two-step MR analysis was used to investigate whether 91 inflammatory proteins mediate the effect of alliin on the risk of cancer. Finally, multivariable MR analysis was conducted to determine the direct effects of alliin on the risk of cancer, with adjustment for potential mediators. Inverse variance weighted results were considered the primary observation outcome, and additional sensitivity analyses were conducted. Increased blood alliin levels were significantly causally associated with decreased risks of prostate cancer, ovarian cancer, breast cancer, cervical cancer, lymphoma, and colorectal cancer, with the corresponding meta-analyses also showing significant associations. In the two-step MR analysis, chemokine ligand 23 (CCL23) and oncostatin M (OSM) as well as interleukin-12B (IL12B) were the key mediators of the inverse causal relationships between blood alliin levels and the risk of prostate cancer as well as the risks of ovarian and colorectal cancers, respectively. STAM-binding protein was a key mediator of the causal relationships between blood alliin levels and the risk of lymphoma. The results of this study support that increased blood alliin levels can reduce the risks of multiple cancers, with circulating inflammatory proteins potentially mediating this association.
- 13 November 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (46) , e51493
Open AccessCirculating inflammatory proteins mediate the causal relationship between blood alliin and cancer: A two-step, multivariable Mendelian randomization study
An association has been found between alliin and reduced risks of various cancers; however, evidence for these causal relationships remain limited. This study utilized Mendelian randomization (MR) analysis to assess the potential causal relationships between circulating alliin levels and the risks of 22 common cancers. We selected instrumental variables from the latest and largest European genome-wide association study (GWAS) datasets. First, we comprehensively assessed the causal relationships between blood alliin levels and the risks of 22 common cancers through two-sample MR analysis. Subsequently, we repeated the validation of instrumental variables using cancer GWAS statistics from different studies and merged the results by meta-analysis. Two-step MR analysis was used to investigate whether 91 inflammatory proteins mediate the effect of alliin on the risk of cancer. Finally, multivariable MR analysis was conducted to determine the direct effects of alliin on the risk of cancer, with adjustment for potential mediators. Inverse variance weighted results were considered the primary observation outcome, and additional sensitivity analyses were conducted. Increased blood alliin levels were significantly causally associated with decreased risks of prostate cancer, ovarian cancer, breast cancer, cervical cancer, lymphoma, and colorectal cancer, with the corresponding meta-analyses also showing significant associations. In the two-step MR analysis, chemokine ligand 23 (CCL23) and oncostatin M (OSM) as well as interleukin-12B (IL12B) were the key mediators of the inverse causal relationships between blood alliin levels and the risk of prostate cancer as well as the risks of ovarian and colorectal cancers, respectively. STAM-binding protein was a key mediator of the causal relationships between blood alliin levels and the risk of lymphoma. The results of this study support that increased blood alliin levels can reduce the risks of multiple cancers, with circulating inflammatory proteins potentially mediating this association.
- Open Access
- 11 April 2026
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 9 (2)
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study
Background: Bladder cancer is the most common urological malignancy. Bladder cancer has limited therapeutic options, especially in advanced stages. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising target for cancer therapy. However, the role of autophagy in modulating ferroptosis remains incompletely understood. Methods: We investigated the anti-tumor effects of JS-K, a nitric oxide-releasing prodrug, in bladder cancer through integrated cell, animal, and patient data studies. In vitro experiments with T24 and UM-UC-3 cells were used to explore how JS-K influences cancer cell survival and the interplay between autophagy and ferroptosis. In vivo, a BALB/c nude mouse tumor model provided a system to examine tumor response and tissue-level changes. To extend these findings to the clinical setting, we analyzed LC3B expression and its associations with ferroptosis-related genes, patient prognosis, and the tumor immune microenvironment. Results: JS-K induced mitochondrial damage, lipid peroxidation, reactive oxygen species accumulation, and intracellular iron overload in bladder cancer cells in a concentration-dependent manner. These changes were accompanied by downregulation of GPX4 and SLC7A11 and upregulation of FTH1 and TFR1, indicative of ferroptosis. Inhibition or knockdown of the autophagy marker LC3B reversed these effects, establishing the role of autophagy in mediating ferroptosis. In xenograft models, JS-K suppressed tumor growth, an effect abrogated by LC3B silencing. Integrated transcriptomic and single-cell analyses revealed a strong correlation between LC3B and ferroptosis-related genes, with CISD1 identified as a key prognostic marker. Conclusions: JS-K induces autophagy-dependent ferroptosis in bladder cancer cells and significantly suppresses tumor progression. Targeting the autophagy–ferroptosis axis offers a novel therapeutic strategy for bladder cancer treatment.
- 11 April 2026
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 9 (2)
Open AccessJS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study
Background: Bladder cancer is the most common urological malignancy. Bladder cancer has limited therapeutic options, especially in advanced stages. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising target for cancer therapy. However, the role of autophagy in modulating ferroptosis remains incompletely understood. Methods: We investigated the anti-tumor effects of JS-K, a nitric oxide-releasing prodrug, in bladder cancer through integrated cell, animal, and patient data studies. In vitro experiments with T24 and UM-UC-3 cells were used to explore how JS-K influences cancer cell survival and the interplay between autophagy and ferroptosis. In vivo, a BALB/c nude mouse tumor model provided a system to examine tumor response and tissue-level changes. To extend these findings to the clinical setting, we analyzed LC3B expression and its associations with ferroptosis-related genes, patient prognosis, and the tumor immune microenvironment. Results: JS-K induced mitochondrial damage, lipid peroxidation, reactive oxygen species accumulation, and intracellular iron overload in bladder cancer cells in a concentration-dependent manner. These changes were accompanied by downregulation of GPX4 and SLC7A11 and upregulation of FTH1 and TFR1, indicative of ferroptosis. Inhibition or knockdown of the autophagy marker LC3B reversed these effects, establishing the role of autophagy in mediating ferroptosis. In xenograft models, JS-K suppressed tumor growth, an effect abrogated by LC3B silencing. Integrated transcriptomic and single-cell analyses revealed a strong correlation between LC3B and ferroptosis-related genes, with CISD1 identified as a key prognostic marker. Conclusions: JS-K induces autophagy-dependent ferroptosis in bladder cancer cells and significantly suppresses tumor progression. Targeting the autophagy–ferroptosis axis offers a novel therapeutic strategy for bladder cancer treatment.
- Open Access
- 1 April 2026
- Published by Springer Nature in Basic and Clinical Andrology
- Vol. 36 (1) , 11
Testicular shear wave elastography in varicocele: measurement strategy and clinical application
Background: Conflicting results on testicular stiffness in varicocele and the lack of a standardized measurement protocol hinder clinical staging. In this study, we aimed to investigate the effects of probe frequency and region of interest (ROI) size selection on testicular stiffness measurements and to evaluate the testicular parenchymal stiffness and volume changes in patients with varicocele compare with healthy controls under standardized conditions. Results: Shear wave elastography (SWE) was first performed on 62 testes from 31 healthy men, with two probe frequencies (SL10–2 and SL15–4) and four ROI sizes (4, 6, 8, and 10 mm), to assess the impact on SWE measurements. Based on the lowest variability settings, testicular volume and stiffness were compared in 76 patients with varicoceles and 68 healthy controls. Different SWE values were obtained with the two probes and four ROI sizes ( p < 0.05). The SL15–4 probe showed lower variability, with the lowest coefficient of variation at the 4 mm ROI. The median testicular SWE value was 2.03 (1.97–2.07) kPa in the control group and 2.01 (1.87–2.07), 1.77 (1.53–1.98), and 1.51 (1.45–1.63) kPa in the Grade I, II, and III varicocele groups, respectively. SWE values were significantly lower in varicocele patients and decreased with increasing grade. The median testicular volumes were 13.08 (12.06–15.70) mL in the control group and 12.26 (10.70–15.15), 13.06 (11.34–14.72), and 11.84 (11.26–12.86) mL in the Grade I, II, and III varicocele groups, respectively. No significant difference in volume was observed between varicocele and control groups ( p = 0.387). Conclusion: Probe frequency and ROI size influence testicular SWE measurements, and caution should be exercised when comparing SWE results. Our study showed that testicular stiffness was decreased in patients with varicocele without significant changes in testicular volume, suggesting the presence of subtle structural alterations. SWE may provide complementary information by detecting changes in testicular parenchymal in patients with varicocele.
- 1 April 2026
- Published by Springer Nature in Basic and Clinical Andrology
- Vol. 36 (1) , 11
Open AccessTesticular shear wave elastography in varicocele: measurement strategy and clinical application
Background: Conflicting results on testicular stiffness in varicocele and the lack of a standardized measurement protocol hinder clinical staging. In this study, we aimed to investigate the effects of probe frequency and region of interest (ROI) size selection on testicular stiffness measurements and to evaluate the testicular parenchymal stiffness and volume changes in patients with varicocele compare with healthy controls under standardized conditions. Results: Shear wave elastography (SWE) was first performed on 62 testes from 31 healthy men, with two probe frequencies (SL10–2 and SL15–4) and four ROI sizes (4, 6, 8, and 10 mm), to assess the impact on SWE measurements. Based on the lowest variability settings, testicular volume and stiffness were compared in 76 patients with varicoceles and 68 healthy controls. Different SWE values were obtained with the two probes and four ROI sizes ( p < 0.05). The SL15–4 probe showed lower variability, with the lowest coefficient of variation at the 4 mm ROI. The median testicular SWE value was 2.03 (1.97–2.07) kPa in the control group and 2.01 (1.87–2.07), 1.77 (1.53–1.98), and 1.51 (1.45–1.63) kPa in the Grade I, II, and III varicocele groups, respectively. SWE values were significantly lower in varicocele patients and decreased with increasing grade. The median testicular volumes were 13.08 (12.06–15.70) mL in the control group and 12.26 (10.70–15.15), 13.06 (11.34–14.72), and 11.84 (11.26–12.86) mL in the Grade I, II, and III varicocele groups, respectively. No significant difference in volume was observed between varicocele and control groups ( p = 0.387). Conclusion: Probe frequency and ROI size influence testicular SWE measurements, and caution should be exercised when comparing SWE results. Our study showed that testicular stiffness was decreased in patients with varicocele without significant changes in testicular volume, suggesting the presence of subtle structural alterations. SWE may provide complementary information by detecting changes in testicular parenchymal in patients with varicocele.
- 24 July 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-7
Comparison of minimally invasive suction-evacuation versus standard nephrostomy sheaths for the treatment of partial staghorn stones
We conducted a prospective, randomized study to compare the safety and efficacy of using a conventional nephrostomy sheath (CNS) versus a minimally invasive suction-evacuation nephrostomy sheath (SENS) for treating partial staghorn stones. Eighty-six patients with partial staghorn stones were randomly assigned into two groups, with 43 patients in each group. One group underwent standard percutaneous nephrolithotomy (sPCNL) using CNS, whereas the other group underwent minimally invasive percutaneous nephrolithotomy (mPCNL) with SENS. Patient demographics, stone characteristics, intraoperative data, perioperative data, and surgical results were collected and analyzed.The patient demographics and stone characteristics were similar in both groups. The SENS group had significantly lower peak and mean intrarenal pressure (IRP) during the procedure. The stone-free rate (SFR) was comparable between groups. The SENS group removed stones more efficiently, with shorter treatment time and less frequent use of the stone extractor. Lower IRP and shorter treatment time led to fewer postoperative complications.mPCNL with SENS results in lower IRP, faster stone removal, and reduced use of stone forceps while preserving SFR and safety.
- 24 July 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-7
Comparison of minimally invasive suction-evacuation versus standard nephrostomy sheaths for the treatment of partial staghorn stones
We conducted a prospective, randomized study to compare the safety and efficacy of using a conventional nephrostomy sheath (CNS) versus a minimally invasive suction-evacuation nephrostomy sheath (SENS) for treating partial staghorn stones. Eighty-six patients with partial staghorn stones were randomly assigned into two groups, with 43 patients in each group. One group underwent standard percutaneous nephrolithotomy (sPCNL) using CNS, whereas the other group underwent minimally invasive percutaneous nephrolithotomy (mPCNL) with SENS. Patient demographics, stone characteristics, intraoperative data, perioperative data, and surgical results were collected and analyzed.The patient demographics and stone characteristics were similar in both groups. The SENS group had significantly lower peak and mean intrarenal pressure (IRP) during the procedure. The stone-free rate (SFR) was comparable between groups. The SENS group removed stones more efficiently, with shorter treatment time and less frequent use of the stone extractor. Lower IRP and shorter treatment time led to fewer postoperative complications.mPCNL with SENS results in lower IRP, faster stone removal, and reduced use of stone forceps while preserving SFR and safety.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 7169-7183
Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In Murine Model
Introduction: The therapeutic efficacy of intravesical agents for bladder cancer (BCa) is frequently constrained by their clearance via urine flushing and periodic bladder emptying, as well as the absence of tumor-targeting capabilities. Consequently, an effective drug delivery system must possess both tumor-targeting and adhesion properties to overcome these limitations. Methods: In this study, we investigated a tumor-selective hydrogel as a potential vehicle for BCa treatment. For the first time in the field of intravesical therapy, we introduced the concept of pre-targeting, sequentially instilling modified polyarginine and membrane nanoparticles into the bladder to achieve selective gelation on the tumor surface. We comprehensively evaluated tumor selectivity, endocytosis pathways, organelle localization, and osmotic capacity, and demonstrated in vivo and in vitro degradation following drug delivery. Results: The pre-targeted hydrogel exhibited superior tumor selectivity. The drug-loaded membrane nanoparticles released during hydrogel degradation were internalized by tumor cells at levels exceeding those in normal cells by more than eightfold. Our findings indicated that this internalization process was energy-dependent and mediated by caveolin. Post-internalization, the drug-loaded membrane nanoparticles localized to the endoplasmic reticulum and Golgi apparatus, with minimal colocalization with lysosomes. Moreover, the hydrogel demonstrated profound penetration into tumor tissue. In terms of antitumor efficacy, the hydrogel loaded with gemcitabine exhibited significantly enhanced therapeutic effects compared to free gemcitabine. Conclusion: Our dual-functional hydrogel system exhibits robust anti-tumor activity against BCa, presenting a promising alternative for intravesical therapy. This innovative approach addresses key limitations of current treatments by combining tumor targeting with sustained drug adhesion, offering a novel strategy for the management of BCa.
- 1 June 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 7169-7183
Open AccessIntravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In Murine Model
Introduction: The therapeutic efficacy of intravesical agents for bladder cancer (BCa) is frequently constrained by their clearance via urine flushing and periodic bladder emptying, as well as the absence of tumor-targeting capabilities. Consequently, an effective drug delivery system must possess both tumor-targeting and adhesion properties to overcome these limitations. Methods: In this study, we investigated a tumor-selective hydrogel as a potential vehicle for BCa treatment. For the first time in the field of intravesical therapy, we introduced the concept of pre-targeting, sequentially instilling modified polyarginine and membrane nanoparticles into the bladder to achieve selective gelation on the tumor surface. We comprehensively evaluated tumor selectivity, endocytosis pathways, organelle localization, and osmotic capacity, and demonstrated in vivo and in vitro degradation following drug delivery. Results: The pre-targeted hydrogel exhibited superior tumor selectivity. The drug-loaded membrane nanoparticles released during hydrogel degradation were internalized by tumor cells at levels exceeding those in normal cells by more than eightfold. Our findings indicated that this internalization process was energy-dependent and mediated by caveolin. Post-internalization, the drug-loaded membrane nanoparticles localized to the endoplasmic reticulum and Golgi apparatus, with minimal colocalization with lysosomes. Moreover, the hydrogel demonstrated profound penetration into tumor tissue. In terms of antitumor efficacy, the hydrogel loaded with gemcitabine exhibited significantly enhanced therapeutic effects compared to free gemcitabine. Conclusion: Our dual-functional hydrogel system exhibits robust anti-tumor activity against BCa, presenting a promising alternative for intravesical therapy. This innovative approach addresses key limitations of current treatments by combining tumor targeting with sustained drug adhesion, offering a novel strategy for the management of BCa.
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (10) , 3127-3154
ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway
Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor samples along with 30 corresponding normal tissues, and Western blotting (WB) analyses across multiple ccRCC-derived cell lines. Functional assays assessing cell proliferation, colony formation capability, migration, invasion, and in vivo tumorigenicity were conducted following either ARPC1B suppression or upregulation. Additionally, WB analysis was utilized to evaluate proteins linked to epithelial-to-mesenchymal transition (EMT) and the Wnt/β-catenin pathway. Results: The findings revealed a substantial elevation of ARPC1B in ccRCC tissues and cell lines, significantly associated with advanced TNM stages, higher Fuhrman grades, and reduced overall survival (OS) (p < 0.001). Multivariate statistical analysis identified ARPC1B as a standalone prognostic factor. Silencing ARPC1B notably impaired ccRCC cellular activities, and tumorigenesis in animal models, whereas augmented ARPC1B expression enhanced these malignant phenotypes. Mechanistically, downregulation of ARPC1B suppressed Wnt/β-catenin signaling and disrupted EMT, indicated by reduced β-catenin, c-Myc, cyclin D1, and ZEB-1 levels, and concurrently increased E-cadherin expression. Additionally, reactivation of the Wnt/β-catenin pathway partly reversed the inhibitory effects of ARPC1B depletion on tumor growth and invasiveness. Conclusions: ARPC1B emerges as an essential oncogenic factor in ccRCC by stimulating EMT and activating the Wnt/β-catenin pathway, ultimately enhancing tumor aggressiveness and metastatic potential. Thus, targeting ARPC1B represents a promising therapeutic strategy, warranting further exploration in ccRCC management.
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (10) , 3127-3154
Open AccessARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway
Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor samples along with 30 corresponding normal tissues, and Western blotting (WB) analyses across multiple ccRCC-derived cell lines. Functional assays assessing cell proliferation, colony formation capability, migration, invasion, and in vivo tumorigenicity were conducted following either ARPC1B suppression or upregulation. Additionally, WB analysis was utilized to evaluate proteins linked to epithelial-to-mesenchymal transition (EMT) and the Wnt/β-catenin pathway. Results: The findings revealed a substantial elevation of ARPC1B in ccRCC tissues and cell lines, significantly associated with advanced TNM stages, higher Fuhrman grades, and reduced overall survival (OS) (p < 0.001). Multivariate statistical analysis identified ARPC1B as a standalone prognostic factor. Silencing ARPC1B notably impaired ccRCC cellular activities, and tumorigenesis in animal models, whereas augmented ARPC1B expression enhanced these malignant phenotypes. Mechanistically, downregulation of ARPC1B suppressed Wnt/β-catenin signaling and disrupted EMT, indicated by reduced β-catenin, c-Myc, cyclin D1, and ZEB-1 levels, and concurrently increased E-cadherin expression. Additionally, reactivation of the Wnt/β-catenin pathway partly reversed the inhibitory effects of ARPC1B depletion on tumor growth and invasiveness. Conclusions: ARPC1B emerges as an essential oncogenic factor in ccRCC by stimulating EMT and activating the Wnt/β-catenin pathway, ultimately enhancing tumor aggressiveness and metastatic potential. Thus, targeting ARPC1B represents a promising therapeutic strategy, warranting further exploration in ccRCC management.
- Open Access
- 7 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (23) , e38433
Blood metabolites mediate the causal relationship between circulating CX3CL1 levels and prostate cancer: A 2-step Mendelian randomization study
Chemokines influence the progression of prostate cancer (PCa) through multiple mechanisms. However, the effect of C-X3-C chemokine ligand 1 (CX3CL1) on PCa risk remains controversial. Our study aimed to investigate whether circulating CX3CL1 is causally associated with PCa and to identify metabolites that have mediating effects using the 2-step bidirectional Mendelian randomization (MR) analysis process. Inverse variance weighting (IVW) results were used as the primary observations, while additional sensitivity analyses were conducted. For each standard deviation increase exhibited by the circulating CX3CL1 levels, the risk of PCa was reduced by 0.4% (IVW: OR = 0.996, [95% CI = 0.994–0.998], P < .001), and blood alliin levels increased by 19% (IVW: OR = 1.185, [95% CI = 1.01–1.54], P = .003). For each standard deviation increase in the blood alliin levels, the risk of PCa was reduced by 0.1% (IVW: OR = 0.999, [95% CI = 0.997–0.999], P = .03). Therefore, the protective effect of circulating CX3CL1 on PCa may be mediated by blood alliin levels (mediated proportion = 6.7%). The results supported the notion that high levels of circulating CX3CL1 indicate a lower PCa risk and the idea that the food-derived antioxidant alliin may mediate this association. We emphasize that the use of CX3CL1 as a protective factor against PCa may provide new strategies for PCa prevention and care in the future.
- 7 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (23) , e38433
Open AccessBlood metabolites mediate the causal relationship between circulating CX3CL1 levels and prostate cancer: A 2-step Mendelian randomization study
Chemokines influence the progression of prostate cancer (PCa) through multiple mechanisms. However, the effect of C-X3-C chemokine ligand 1 (CX3CL1) on PCa risk remains controversial. Our study aimed to investigate whether circulating CX3CL1 is causally associated with PCa and to identify metabolites that have mediating effects using the 2-step bidirectional Mendelian randomization (MR) analysis process. Inverse variance weighting (IVW) results were used as the primary observations, while additional sensitivity analyses were conducted. For each standard deviation increase exhibited by the circulating CX3CL1 levels, the risk of PCa was reduced by 0.4% (IVW: OR = 0.996, [95% CI = 0.994–0.998], P < .001), and blood alliin levels increased by 19% (IVW: OR = 1.185, [95% CI = 1.01–1.54], P = .003). For each standard deviation increase in the blood alliin levels, the risk of PCa was reduced by 0.1% (IVW: OR = 0.999, [95% CI = 0.997–0.999], P = .03). Therefore, the protective effect of circulating CX3CL1 on PCa may be mediated by blood alliin levels (mediated proportion = 6.7%). The results supported the notion that high levels of circulating CX3CL1 indicate a lower PCa risk and the idea that the food-derived antioxidant alliin may mediate this association. We emphasize that the use of CX3CL1 as a protective factor against PCa may provide new strategies for PCa prevention and care in the future.
An integrated approach for improving clinical management of non‐obstructive azoospermia
Background: Non‐obstructive azoospermia is the most severe form of male infertility. A testicular biopsy is required for the diagnosis of non‐obstructive azoospermia, and the causal factors for non‐obstructive azoospermia remain unknown.Objectives: To reduce the risk of multiple biopsies and identify factors that contribute to non‐obstructive azoospermia, we proposed an integrated approach for the preoperative diagnosis and clinical management of non‐obstructive azoospermia by applying the chromosome‐spreading technique and whole‐exome sequencing.Materials and Methods: Between July 2020 and December 2022, after ruling out definitive obstructive azoospermia and non‐obstructive azoospermia patients with testicular volume < 6 mL, 20 patients with non‐obstructive azoospermia who underwent preoperative testicular diagnostic biopsy using testicular sperm aspiration were subjected to retrospective analysis.Results: Microscopic examination identified four patients with sperm cells, and 16 without sperm cells. Routine pathological analysis classified one patient as normal spermatogenesis, three as hypospermatogenesis, five as maturation arrest, nine as Sertoli cell‐only, and two as unable to judge. With chromosome‐spreading technology using routine cell suspension samples for microscopic examination, 18 patient diagnoses were validated, and two patients without a definitive diagnosis were supplemented. Detection of the Y chromosome and a well‐organized whole‐exome sequencing analysis revealed potential genetic factors.Discussion and Conclusion: The full use of testicular biopsy is beneficial for the diagnosis of azoospermia, as it avoids the risk of multiple biopsies. Moreover, in combination with whole‐exome sequencing, clinicians can obtain more information regarding the pathogenesis of non‐obstructive azoospermia, which may guide treatment.
An integrated approach for improving clinical management of non‐obstructive azoospermia
Background: Non‐obstructive azoospermia is the most severe form of male infertility. A testicular biopsy is required for the diagnosis of non‐obstructive azoospermia, and the causal factors for non‐obstructive azoospermia remain unknown.Objectives: To reduce the risk of multiple biopsies and identify factors that contribute to non‐obstructive azoospermia, we proposed an integrated approach for the preoperative diagnosis and clinical management of non‐obstructive azoospermia by applying the chromosome‐spreading technique and whole‐exome sequencing.Materials and Methods: Between July 2020 and December 2022, after ruling out definitive obstructive azoospermia and non‐obstructive azoospermia patients with testicular volume < 6 mL, 20 patients with non‐obstructive azoospermia who underwent preoperative testicular diagnostic biopsy using testicular sperm aspiration were subjected to retrospective analysis.Results: Microscopic examination identified four patients with sperm cells, and 16 without sperm cells. Routine pathological analysis classified one patient as normal spermatogenesis, three as hypospermatogenesis, five as maturation arrest, nine as Sertoli cell‐only, and two as unable to judge. With chromosome‐spreading technology using routine cell suspension samples for microscopic examination, 18 patient diagnoses were validated, and two patients without a definitive diagnosis were supplemented. Detection of the Y chromosome and a well‐organized whole‐exome sequencing analysis revealed potential genetic factors.Discussion and Conclusion: The full use of testicular biopsy is beneficial for the diagnosis of azoospermia, as it avoids the risk of multiple biopsies. Moreover, in combination with whole‐exome sequencing, clinicians can obtain more information regarding the pathogenesis of non‐obstructive azoospermia, which may guide treatment.
- 14 May 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (7) , 1-8
The initial experience of 4.5/6.5 Fr ureteroscopic laser lithotripsy under topical intraurethral anesthesia supplemented by preoperative and intraoperative medications
Purpose To assess the safety and effectiveness of the 4.5/6.5 Fr ureteroscopic laser lithotripsy (URSL) under topical intraurethral anesthesia (TIUA) compared to spinal anesthesia (SA). Methods A retrospective study was conducted on 47 (TIUA: SA = 23:24) patients receiving 4.5/6.5 Fr URSL from July 2022 to September 2022. For the TIUA group, atropine, pethidine, and phloroglucinol were used apart from lidocaine. In the SA group, patients received lidocaine and bupivacaine. We compare the two groups including stone-free rate (SFR), procedure time, anesthesia time, overall operative time, hospital stay, anesthesia failure, intraoperative pain, need for additional analgesia, cost, and complications. Results The conversion rate in the TIUA group was 4.35% (1/23). SFR was 100% in both groups. Surgical waiting time and anesthesia time were longer in the SA group (P < 0.001). There were no statistical differences in operational time and intraoperative pain. Patients developed grade 0–1 ureteral injuries. Post-surgical time out of bed was noticeably faster in the TIUA group (P < 0.001). The post-operative complication rate including vomiting and back pain was lower in the TIUA group (P = 0.005). Conclusion TIUA had an equal surgical success rate and controlled patients’ intraoperative pain as SA. It was superior in terms of TIUA’s patient admission, waiting time for surgery, anesthesia time, post-operative time out of bed, low complications, and costs, especially for females.
- 14 May 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (7) , 1-8
The initial experience of 4.5/6.5 Fr ureteroscopic laser lithotripsy under topical intraurethral anesthesia supplemented by preoperative and intraoperative medications
Purpose To assess the safety and effectiveness of the 4.5/6.5 Fr ureteroscopic laser lithotripsy (URSL) under topical intraurethral anesthesia (TIUA) compared to spinal anesthesia (SA). Methods A retrospective study was conducted on 47 (TIUA: SA = 23:24) patients receiving 4.5/6.5 Fr URSL from July 2022 to September 2022. For the TIUA group, atropine, pethidine, and phloroglucinol were used apart from lidocaine. In the SA group, patients received lidocaine and bupivacaine. We compare the two groups including stone-free rate (SFR), procedure time, anesthesia time, overall operative time, hospital stay, anesthesia failure, intraoperative pain, need for additional analgesia, cost, and complications. Results The conversion rate in the TIUA group was 4.35% (1/23). SFR was 100% in both groups. Surgical waiting time and anesthesia time were longer in the SA group (P < 0.001). There were no statistical differences in operational time and intraoperative pain. Patients developed grade 0–1 ureteral injuries. Post-surgical time out of bed was noticeably faster in the TIUA group (P < 0.001). The post-operative complication rate including vomiting and back pain was lower in the TIUA group (P = 0.005). Conclusion TIUA had an equal surgical success rate and controlled patients’ intraoperative pain as SA. It was superior in terms of TIUA’s patient admission, waiting time for surgery, anesthesia time, post-operative time out of bed, low complications, and costs, especially for females.
- Open Access
- 28 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 949058
Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database
Objectives: Clear cell renal cell carcinoma (ccRCC) is highly prevalent, prone to metastasis, and has a poor prognosis after metastasis. Therefore, this study aimed to develop a prognostic model to predict the individualized prognosis of patients with metastatic clear cell renal cell carcinoma (mccRCC).Patients and Methods: Data of 1790 patients with mccRCC, registered from 2010 to 2015, were extracted from the Surveillance, Epidemiology and End Results (SEER) database. The included patients were randomly divided into a training set (n = 1253) and a validation set (n = 537) based on the ratio of 7:3. The univariate and multivariate Cox regression analyses were used to identify the important independent prognostic factors. A nomogram was then constructed to predict cancer specific survival (CSS). The performance of the nomogram was internally validated by using the concordance index (C-index), calibration plots, receiver operating characteristic curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). We compared the nomogram with the TNM staging system. Kaplan–Meier survival analysis was applied to validate the application of the risk stratification system.Results: Diagnostic age, T-stage, N-stage, bone metastases, brain metastases, liver metastases, lung metastases, chemotherapy, radiotherapy, surgery, and histological grade were identified as independent predictors of CSS. The C-index of training and validation sets are 0.707 and 0.650 respectively. In the training set, the AUC of CSS predicted by nomogram in patients with mccRCC at 1-, 3- and 5-years were 0.770, 0.758, and 0.757, respectively. And that in the validation set were 0.717, 0.700, and 0.700 respectively. Calibration plots also showed great prediction accuracy. Compared with the TNM staging system, NRI and IDI results showed that the predictive ability of the nomogram was greatly improved, and DCA showed that patients obtained clinical benefits. The risk stratification system can significantly distinguish the patients with different survival risks.Conclusion: In this study, we developed and validated a nomogram to predict the CSS rate in patients with mccRCC. It showed consistent reliability and clinical applicability. Nomogram may assist clinicians in evaluating the risk factors of patients and formulating an optimal individualized treatment strategy.
- 28 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 949058
Open AccessDevelopment and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database
Objectives: Clear cell renal cell carcinoma (ccRCC) is highly prevalent, prone to metastasis, and has a poor prognosis after metastasis. Therefore, this study aimed to develop a prognostic model to predict the individualized prognosis of patients with metastatic clear cell renal cell carcinoma (mccRCC).Patients and Methods: Data of 1790 patients with mccRCC, registered from 2010 to 2015, were extracted from the Surveillance, Epidemiology and End Results (SEER) database. The included patients were randomly divided into a training set (n = 1253) and a validation set (n = 537) based on the ratio of 7:3. The univariate and multivariate Cox regression analyses were used to identify the important independent prognostic factors. A nomogram was then constructed to predict cancer specific survival (CSS). The performance of the nomogram was internally validated by using the concordance index (C-index), calibration plots, receiver operating characteristic curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). We compared the nomogram with the TNM staging system. Kaplan–Meier survival analysis was applied to validate the application of the risk stratification system.Results: Diagnostic age, T-stage, N-stage, bone metastases, brain metastases, liver metastases, lung metastases, chemotherapy, radiotherapy, surgery, and histological grade were identified as independent predictors of CSS. The C-index of training and validation sets are 0.707 and 0.650 respectively. In the training set, the AUC of CSS predicted by nomogram in patients with mccRCC at 1-, 3- and 5-years were 0.770, 0.758, and 0.757, respectively. And that in the validation set were 0.717, 0.700, and 0.700 respectively. Calibration plots also showed great prediction accuracy. Compared with the TNM staging system, NRI and IDI results showed that the predictive ability of the nomogram was greatly improved, and DCA showed that patients obtained clinical benefits. The risk stratification system can significantly distinguish the patients with different survival risks.Conclusion: In this study, we developed and validated a nomogram to predict the CSS rate in patients with mccRCC. It showed consistent reliability and clinical applicability. Nomogram may assist clinicians in evaluating the risk factors of patients and formulating an optimal individualized treatment strategy.